FDA panel votes against Xgeva for prostate cancer
WASHINGTON (AP) — A panel of cancer experts voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients.
The Food and Drug Administration's cancer drug panel voted 12-1 that the benefits of the drug did not outweigh its risks, which included bone disease in about 6 percent of patient...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
